Mitotane induces mitochondrial membrane depolarization and apoptosis in thyroid cancer cells

Bikas,Athanasios; Jensen,Kirk; Patel,Aneeta; Costello,John; Kaltsas,Gregory; Hoperia,Victoria; Wartofsky,Leonard; Burman,Kenneth; Vasko,Vasyl

doi:10.3892/ijo.2019.4802

Mitotane induces mitochondrial membrane depolarization and apoptosis in thyroid cancer cells

Authors:
- Athanasios Bikas
- Kirk Jensen
- Aneeta Patel
- John Costello
- Gregory Kaltsas
- Victoria Hoperia
- Leonard Wartofsky
- Kenneth Burman
- Vasyl Vasko
View Affiliations

Affiliations: Department of Pathophysiology, Laiko Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece, Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA, Department of Fundamental Medicine, National University of Kyiv, 01033 Kyiv, Ukraine, Division of Endocrinology, Department of Internal Medicine, MedStar Washington Hospital Center, Washington, DC 20010, USA
Published online on: May 16, 2019 https://doi.org/10.3892/ijo.2019.4802
Pages: 7-20
Copyright: © Bikas et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mitotane is used for the treatment of adrenocortical cancer and elicits its anticancer effects via inhibition of mitochondrial respiration. Targeting mitochondria‑dependent metabolism has emerged as a promising strategy for thyroid cancer (TC) treatment. We hypothesized that mitotane targets mitochondria and induces apoptosis in TC cells. Cell lines representative of the major histological variants of TC were chosen: Follicular (FTC‑133), poorly differentiated (BCPAP), anaplastic (SW1736 and C643) and medullary (TT) TC cells, and were treated with mitotane (0‑100 µM). Mitochondrial membrane potential, cell viability and apoptosis were examined by JC‑1 staining and by western blot analysis using an antibody against caspase‑3. The expression of mitochondrial molecules and DNA damage markers and the activation of endoplasmic reticulum (ER) stress were determined by western blotting. The expression of mitochondrial ATP synthase subunit β (ATP5B) was examined by immunostaining in 100 human TC tissue samples. Treatment with mitotane (50 µM for 24 h) decreased the viability of FTC‑133, BCPAP, SW1736, C643 and TT cells by 12, 59, 54, 31 and 66%, respectively. Morphological evidence of ER stress and overexpression of ER markers was observed in TC cells following exposure to mitotane. The treatment led to increased expression of histone γH2AX, indicating DNA damage, and to caspase‑3 cleavage. Consistent with the results of the cell viability assays, the overexpression of pro‑apoptotic genes following treatment with mitotane was more prominent in TC cells harboring mutations in the serine/threonine‑protein kinase B‑raf gene and proto‑oncogene tyrosine‑protein kinase receptor Ret. Treatment with mitotane was associated with loss of mitochondrial membrane potential and decreased expression of ATP5B, particularly in the medullary TC (MTC)‑derived TT cells. Immunohistochemical analysis of mitochondrial ATP5B in human TC specimens demonstrated its overexpression in cancer compared with normal thyroid tissue. The level of ATP5B expression was higher in MTC compared with the follicular, papillary or anaplastic types of TC. Mitotane elicited pleiotropic effects on TC cells, including induction of ER stress, inhibition of mitochondrial membrane potential and induction of apoptosis. The results of the present study suggest that mitotane could be considered as a novel agent for the treatment of aggressive types of TC.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar
2	Ahn HS, Kim HJ and Welch HG: Korea's thyroid-cancer 'epidemic' - screening and overdiagnosis. N Engl J Med. 371:1765–1767. 2014. View Article : Google Scholar : PubMed/NCBI
3	Chen AY, Jemal A and Ward EM: Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 115:3801–3807. 2009. View Article : Google Scholar : PubMed/NCBI
4	Schlumberger MJ: Papillary and follicular thyroid carcinoma. N Engl J Med. 338:297–306. 1998. View Article : Google Scholar : PubMed/NCBI
5	Sherman SI: Thyroid carcinoma. Lancet. 361:501–511. 2003. View Article : Google Scholar : PubMed/NCBI
6	Muresan MM, Olivier P, Leclère J, Sirveaux F, Brunaud L, Klein M, Zarnegar R and Weryha G: Bone metastases from differentiated thyroid carcinoma. Endocr Relat Cancer. 15:37–49. 2008. View Article : Google Scholar : PubMed/NCBI
7	Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, Caillou B, Travagli JP and Parmentier C: Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer. 55:794–804. 1985. View Article : Google Scholar : PubMed/NCBI
8	Smallridge RC and Copland JA: Anaplastic thyroid carcinoma: Pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol). 22:486–497. 2010. View Article : Google Scholar
9	Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal MS, et al American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce: American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 22:1104–1139. 2012. View Article : Google Scholar : PubMed/NCBI
10	Nosé V: Familial thyroid cancer: A review. Mod Pathol. 24(Suppl 2): S19–S33. 2011. View Article : Google Scholar : PubMed/NCBI
11	Williams SD, Birch R and Einhorn LH: Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: A Southeastern Cancer Study Group Trial. Cancer Treat Rep. 70:405–407. 1986.PubMed/NCBI
12	Bikas A, Vachhani S, Jensen K, Vasko V and Burman KD: Targeted therapies in thyroid cancer: An extensive review of the literature. Expert Rev Clin Pharmacol. 9:1299–1313. 2016. View Article : Google Scholar : PubMed/NCBI
13	Kushchayeva Y, Jensen K, Burman KD and Vasko V: Repositioning therapy for thyroid cancer: New insights on established medications. Endocr Relat Cancer. 21:R183–R194. 2014. View Article : Google Scholar : PubMed/NCBI
14	Jensen K, Bikas A, Patel A, Kushchayeva Y, Costello J, McDaniel D, Burman K and Vasko V: Nelfinavir inhibits proliferation and induces DNA damage in thyroid cancer cells. Endocr Relat Cancer. 24:147–156. 2017. View Article : Google Scholar : PubMed/NCBI
15	Kushchayeva Y, Jensen K, Recupero A, Costello J, Patel A, Klubo-Gwiezdzinska J, Boyle L, Burman K and Vasko V: The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells. J Clin Endocrinol Metab. 99:E734–E745. 2014. View Article : Google Scholar : PubMed/NCBI
16	Klubo-Gwiezdzinska J, Jensen K, Costello J, Patel A, Hoperia V, Bauer A, Burman KD, Wartofsky L and Vasko V: Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. Endocr Relat Cancer. 19:447–456. 2012. View Article : Google Scholar : PubMed/NCBI
17	Thakur S, Daley B, Gaskins K, Vasko VV, Boufraqech M, Patel D, Sourbier C, Reece J, Cheng SY, Kebebew E, et al: Metformin targets mitochondrial glycerophosphate dehydrogenase to control rate of oxidative phosphorylation and growth of thyroid cancer in vitro and in vivo. Clin Cancer Res. 24:4030–4043. 2018. View Article : Google Scholar : PubMed/NCBI
18	Baudry C, Coste J, Bou Khalil R, Silvera S, Guignat L, Guibourdenche J, Abbas H, Legmann P, Bertagna X and Bertherat J: Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center. Eur J Endocrinol. 167:473–481. 2012. View Article : Google Scholar : PubMed/NCBI
19	Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F and Fassnacht M; Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 23(Suppl 7): vii131–vii138. 2012. View Article : Google Scholar
20	Henley DJ, van Heerden JA, Grant CS, Carney JA and Carpenter PC: Adrenal cortical carcinoma - a continuing challenge. Surgery. 94:926–931. 1983.PubMed/NCBI
21	Hescot S, Slama A, Lombès A, Paci A, Remy H, Leboulleux S, Chadarevian R, Trabado S, Amazit L, Young J, et al: Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocr Relat Cancer. 20:371–381. 2013. View Article : Google Scholar : PubMed/NCBI
22	Poli G, Guasti D, Rapizzi E, Fucci R, Canu L, Bandini A, Cini N, Bani D, Mannelli M and Luconi M: Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells. Endocr Relat Cancer. 20:537–550. 2013. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
24	Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M and Worden FP: Management of patients with adrenal cancer: Recommendations of an international consensus conference. Endocr Relat Cancer. 12:667–680. 2005. View Article : Google Scholar : PubMed/NCBI
25	Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ and Krans HM: Optimal treatment of adrenocortical carcinoma with mitotane: Results in a consecutive series of 96 patients. Br J Cancer. 69:947–951. 1994. View Article : Google Scholar : PubMed/NCBI
26	Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, Daffara F, Berruti A, Chadarevian R, Schlumberger M, et al: Plasma concentrations of o, p'DDD, o, p'DDA, and o, p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: Results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab. 96:1844–1851. 2011. View Article : Google Scholar : PubMed/NCBI
27	van Slooten H, Moolenaar AJ, van Seters AP and Smeenk D: The treatment of adrenocortical carcinoma with o, p'-DDD: Prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol. 20:47–53. 1984. View Article : Google Scholar : PubMed/NCBI
28	Baudin E; Endocrine Tumor Board of Gustave Roussy: Adrenocortical carcinoma. Endocrinol Metab Clin North Am. 44:411–434. 2015. View Article : Google Scholar : PubMed/NCBI
29	Lehmann TP, Wrzesiński T and Jagodziński PP: The effect of mitotane on viability, steroidogenesis and gene expression in NCI-H295R adrenocortical cells. Mol Med Rep. 7:893–900. 2013. View Article : Google Scholar
30	Waszut U, Szyszka P and Dworakowska D: Understanding mitotane mode of action. J Physiol Pharmacol. 68:13–26. 2017.PubMed/NCBI
31	Pinton P, Giorgi C, Siviero R, Zecchini E and Rizzuto R: Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis. Oncogene. 27:6407–6418. 2008. View Article : Google Scholar : PubMed/NCBI
32	Sbiera S, Leich E, Liebisch G, Sbiera I, Schirbel A, Wiemer L, Matysik S, Eckhardt C, Gardill F, Gehl A, et al: Mitotane inhibits sterol-O-acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology. 156:3895–3908. 2015. View Article : Google Scholar : PubMed/NCBI
33	Fang VS: Cytotoxic activity of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (mitotane) and its analogs on feminizing adrenal neoplastic cells in culture. Cancer Res. 39:139–145. 1979.PubMed/NCBI
34	Hescot S, Amazit L, Lhomme M, Travers S, DuBow A, Battini S, Boulate G, Namer IJ, Lombes A, Kontush A, et al: Identifying mitotane-induced mitochondria-associated membranes dysfunctions: Metabolomic and lipidomic approaches. Oncotarget. 8:109924–109940. 2017. View Article : Google Scholar
35	Whelan SP and Zuckerbraun BS: Mitochondrial signaling: Forwards, backwards, and in between. Oxid Med Cell Longev. 2013:3516132013. View Article : Google Scholar : PubMed/NCBI
36	Chen H and Chan DC: Physiological functions of mitochondrial fusion. Ann N Y Acad Sci. 1201:21–25. 2010. View Article : Google Scholar : PubMed/NCBI
37	Hutter AM Jr and Kayhoe DE: Adrenal cortical carcinoma. Clinical features of 138 patients. Am J Med. 41:572–580. 1966. View Article : Google Scholar : PubMed/NCBI
38	Veytsman I, Nieman L and Fojo T: Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol. 27:4619–4629. 2009. View Article : Google Scholar : PubMed/NCBI
39	Creemers SG, Hofland LJ, Korpershoek E, Franssen GJ, van Kemenade FJ, de Herder WW and Feelders RA: Future directions in the diagnosis and medical treatment of adrenocortical carcinoma. Endocr Relat Cancer. 23:R43–R69. 2016. View Article : Google Scholar
40	Morishita K, Okumura H, Ito N and Takahashi N: Primary culture system of adrenocortical cells from dogs to evaluate direct effects of chemicals on steroidogenesis. Toxicology. 165:171–178. 2001. View Article : Google Scholar : PubMed/NCBI
41	Zatelli MC, Gentilin E, Daffara F, Tagliati F, Reimondo G, Carandina G, Ambrosio MR, Terzolo M and Degli Uberti EC: Therapeutic concentrations of mitotane (o, p'-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. Endocrinology. 151:2453–2461. 2010. View Article : Google Scholar : PubMed/NCBI
42	Russo M, Scollo C, Pellegriti G, Cotta OR, Squatrito S, Frasca F, Cannavò S and Gullo D: Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism. Clin Endocrinol (Oxf). 84:614–619. 2016. View Article : Google Scholar
43	Chortis V, Taylor AE, Schneider P, Tomlinson JW, Hughes BA, O'Neil DM, Libé R, Allolio B, Bertagna X, Bertherat J, et al: Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab. 98:161–171. 2013. View Article : Google Scholar
44	van Staveren WC, Solís DW, Delys L, Duprez L, Andry G, Franc B, Thomas G, Libert F, Dumont JE, Detours V, et al: Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype. Cancer Res. 67:8113–8120. 2007. View Article : Google Scholar : PubMed/NCBI
45	Saiselet M, Floor S, Tarabichi M, Dom G, Hébrant A, van Staveren WC and Maenhaut C: Thyroid cancer cell lines: An overview. Front Endocrinol (Lausanne). 3:1332012. View Article : Google Scholar
46	Salehian B, Liem SY, Mojazi Amiri H and Maghami E: Clinical Trials in Management of Anaplastic Thyroid Carcinoma; Progressions and Set Backs: A Systematic Review. Int J Endocrinol Metab. 17:e677592019.PubMed/NCBI
47	Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu SP, Bal C, Marur S, Gramza A, Yosef RB, Gitlitz B, et al: Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid. 24:232–240. 2014. View Article : Google Scholar